Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Critically, the peptide showed therapeutic efficacy even when administered after neurotoxin exposure
In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-week clinical study
Clinical development documentation
US$ 28.38
US$ 29.23
US$ 27.17
US$ 26.48
